GI CANCERS

ASKB589 exhibited anti-tumor activity when used alongside capecitabine and oxaliplatin, along with sintilimab, for the treatment of gastric or gastroesophageal junction cancers.

In patients who were administered nivolumab in conjunction with chemotherapy, there were enhancements observed in both overall survival and progression-free survival compared to those who received chemotherapy alone.

Findings from an observational investigation revealed that the combination of nivolumab and chemotherapy contributed to improve survival in individuals diagnosed with advanced gastrointestinal cancers.

The latest advances regarding local and systemic regulatory mechanisms of immune responses in cold and hot tumors will be an important topic explored during the 9th Annual School of Gastrointestinal Oncology.

At 12 months, patients in the experimental arm showed OS rates of 14.4% compared with 11.1% for patients receiving chemotherapy alone in the phase 3, open-label CheckMate649 study.

With an investigational new drug application cleared by the FDA, a multi-center, open-label, modified dose-escalation, phase 1b trial of ACT-IOP-003 will begin in pancreatic cancer.

Igor Astsaturov, MD, PhD, discusses the planned phase 1 trial of LP-184 in multiple advanced solid tumors and central nervous system cancers, including pancreatic cancer.

In an interview with Targeted Oncology, Igor Astsaturov, MD, PhD, discussed what led to the development of LP-184 and explained how the agent will be evaluated moving forward.

A phase 1 study investigating padeliporfin vascular targeted photodynamic in patients with unresectable pancreatic adenocarcinoma will begin following the FDA clearance of an investigational new drug application.

The phase 3 RELATIVITY-123 trial in metastatic microsatellite stable colorectal cancer is not expected to meet its primary end point upon completion and is being discontinued due to futility.

Recent findings identified that overall and cancer-specific mortality risks were lowered in patients who used antidepressants following a diagnosis with hepatocellular carcinoma compared with patients that did not.

New guidelines for gastroenteropancreatic neuroendocrine tumors were issued by the American Society of Clinical Oncology and geared toward community oncologists who often encounter these rare and complex cases infrequently.

Mohamad Adham Salkeni, MD, FRCPC, discusses the mechanism of action of ivaltinostat and what rationalizes its use in combination with capecitabine for patients with metastatic pancreatic adenocarcinoma.

In an interview with Targeted Oncology, Chris Haqq, MD, PhD, discussed the potential use of cancer vaccines in patients with KRAS-mutated pancreatic and colon cancer.

Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key gastrointestinal cancer data updates discussed following the 2023 ESMO Congress Meeting.

Rachna Shroff, MD, details key data from the phase III GASTFOX study comparing FOLFOX to docetaxel (TFOX) in the first line treatment of advanced gastric cancer.

Expert medical oncologists review data from the CABINET trial evaluating cabozantinib compared with placebo in two cohorts of previously treated patients with neuroendocrine tumors.

Rachna Shroff, MD, chief of the Division of Hematology and Oncology in the Department of Medicine at the University of Arizona College of Medicine, highlights key data from the Codebreak300 study evaluating if the combination of sotorasib and panitumumab is superior to standard-of-care trifluridine/tipiracil or regorafenib in the setting of chemorefractory metastatic colorectal cancer.

Pembrolizumab and fluoropyrimidine- and platinum-containing chemotherapy are now FDA-approved for the treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

This companion diagnostic tool, which is already approved for use in 5 other cancer types, identifies patients who may be suited for treatment with pembrolizumab.

In an interview for World Neuroendocrine Cancer Awareness Day, Casey J. Allen, MD, discussed the advances in treatment for these patients with gastrointestinal neuroendocrine tumors.

TX-030, a potential first-in-class, anti-CD39 antibody, is being evaluated in a phase 2 trial in metastatic pancreatic ductal adenocarcinoma.

The phase 3 EMERALD-1 trial has met its primary end point and continues to assess durvalumab combined with transarterial chemoembolization and bevacizumab for the secondary end point of overall survival in patients with hepatocellular carcinoma.

The updated indication limits the use of pembrolizumab and chemotherapy to tumors expressing PD-L1 as determined by an FDA-approved test.

Fruquintinib is a new, well-tolerated option for the treatment of patients with refractory metastatic colorectal cancer.

Combining sotorasib and panitumumab improved progression-free survival for patients with KRAS G12C mutation in metastatic colorectal cancer, based on the phase 3 CodeBreaK 300 trial.

CMG901 was active and had a manageable safety profile in a heavily pretreated population of patients with CLDN18.2-positive gastric/gastroesophageal junction cancer.

Irrespective of PD-L1 expression, patients treated with domvanalimab, zimberelimab, and chemotherapy in arm A1 of the phase 2 EDGE-Gastric study demonstrated promising overall response rate and 6-month progression-free survival results.

Encouraging progression-free survival and ctDNA molecular response rates were seen with SD-101 delivered via pressure-enabled drug delivery plus intravenous checkpoint inhibitors in patients with metastatic uveal melanoma with liver metastases.

The approval of pembrolizumab with gemcitabine and cisplatin offers a new immunotherapy regimen for patients with locally advanced unresectable or metastatic biliary tract cancer.